Toronto-based Laborie Medical Technologies will acquire Minnetonka, Minn.-based Cogentix Medical for $239 million.
Here are three things to know about the deal.
1. Cogentix manufactures various urology and endourology products. The company was formed via the merger of two devicemakers — Uroplasty and Vision-Sciences — in 2015, according to StarTribune.
2. Laborie, a urology health company, will acquire Cogentix for $3.85 per share, representing a 28 percent premium over the stock's average closing price in the last 30 days.
3. Cogentix expects the deal to close in the second quarter of 2018.
More articles on supply chain:
Pfizer sells neurology drug to Biogen in nearly $600M deal: 4 things to know
4 latest FDA approval
FDA approves world's smallest heart valve for newborns